COMPOUNDS AND THEIR USES TO RELIEVE SYMPTOMS ASSOCIATED WITH MENOPAUSE
Patent Information
- Application Number
- MA52292
- Authority / Receiving Office
- MA · MA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-04-19
- Filing Date
- 2019-04-19
- Publication Date
- 2021-02-24
- Estimated Expiration
- 2039-04-19
AI Technical Summary
Current hormone replacement therapies for menopause-associated symptoms, particularly vasomotor symptoms, often require higher doses of estetrol and are associated with significant side effects, with the minimal effective dose for alleviating symptoms not clearly defined and varying safety profiles across different dosages.
Administration of a daily dose of 15 mg of estetrol, considering both the frequency and severity of vasomotor symptoms, along with a progestogenic component like drospirenone or progesterone, to achieve effective symptom relief while minimizing side effects and improving quality of life, as assessed by standardized questionnaires like MRS and MENQOL.
The 15 mg daily dose of estetrol effectively reduces the frequency and severity of menopause-associated symptoms, improves quality of life, and provides a better safety profile compared to lower doses, with a significant reduction in adverse events and biopsy requirements, indicating a favorable therapeutic index.